Tafamidis Tied to 74% Lower Death Risk in Matched Real-World Heart Amyloidosis Cohort
A matched real-world cohort analysis found that patients with transthyretin amyloid cardiomyopathy treated with tafamidis had a 74% lower risk ...
A matched real-world cohort analysis found that patients with transthyretin amyloid cardiomyopathy treated with tafamidis had a 74% lower risk ...
A pooled analysis of 1924 tafamidis-treated patients found women made up 11.1 percent of the cohort, more often carried hereditary ...
A pooled real-world analysis of 1,924 patients with transthyretin amyloid cardiomyopathy treated with tafamidis found that outcomes in patients aged ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.